Bio-Connect

Angiopoietin-2 ELISA

Research Use Only
BI-ANG2
Biomedica
Assay Sample Typeserum, EDTA plasma, citrate plasma, heparın plasma, urine, cell culture supernatant
Product group Assays
Price on request
96 tests
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Biomedica
  • Product Name
    Human Angiopoietin-2 ELISA
  • Delivery Days Customer
    7
  • Applications
    ELISA
  • Applications Supplier
    ELISA
  • Assay Detection Range
    3.7-400 pmol/l
  • Assay Precision
    intra-assay: 6%, inter-assay: 8%
  • Assay Sample Type
    serum, EDTA plasma, citrate plasma, heparın plasma, urine, cell culture supernatant
  • Assay Sensitivity
    3.7 pmol/l
  • Assay Specificity
    human Angiopoietin
  • Assay Test Principle
    Sandwich ELISA
  • Assay Time
    3.5h
  • Category Supplier
    Assay
  • Certification
    Research Use Only
  • Scientific Description
    Product Characteristics: The Human Angiopoietin-2 immunoassay is a 3.5 h, 96-well sandwich ELISA for the quantitative determination of Angiopoietin-2 in serum and plasma. Target Information: Angiopoietin-2 (ANG2) is a glycosylated growth factor that is specific for endothelial cells (ECs). ANG2 is expressed in embryonic vessels and contributes to the formation of new vasculature. In adults, it is restricted to sites of vascular remodeling (e.g. ovary, uterus, placenta) and wound healing. ANG2 is regulated by the cytokine vascular endothelial growth factor (VEGF). Together with VEGF, ANG2 induces endothelial cell migration, proliferation, and vascular sprouting. During angiogenesis, ANG2 exerts its effects via the angiopoietin-1/TIE2 receptor signaling system on endothelial cells. Disruption of this signaling leads to the loss of endothelial integrity. In consequence, the endothelium responds to various pro-inflammatory cytokines and growth factors. Thus, ANG2 might cause vascular micro-inflammation in patients with chronic kidney disease (CKD). Various studies demonstrated that ANG2 levels increase with CKD stage and are associated with fluid overload and abnormal cardiac structure. Furthermore, ANG2 concentrations correlate with mortality in patients with CKD stages 4-5. Although ANG2 levels recover after successful kidney transplantation, ANG2 continues to be a cardiovascular risk factor in this population. In cancer, targeting the TIE2-Angiopoietin pathway has shown promising results in some pre-clinical and clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas.
  • Storage Instruction
    2-8°C
  • UNSPSC
    41116133

References

  • Biomedica citations for human Angiopoietin-2 ELISA, BI-ANG2
    Read more